OBJECTIVE： To observe clinical efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in uremic patients underwent maintenance hemodialysis. METHODS： A total of 142 uremic patients with hyperphosphatemia underwent maintenance hemodialysis were selected from Xinqiao Hospital of Third Military Medical University and Chongqing Banan District Hospital of TCM during Jan. 2012-Dec. 2016. They were given Lanthanum carbonate chewable tablets with initial dose of 250 mg， tid， when serum phosphate level ranged 1.78-2.26 mmol/L or with initial dose of 500 mg， tid， when serum phosphate level was ＞2.26 mmol/L. Drug dosage was adjusted according the level of serum phosphate during treatment. After 1， 2， 3 months of treatment， the levels of serum phosphate， serum calcium， albumin， parathyroid hormone （PTH） and alkaline phosphatase were detected and the corrected product of serum calcium and calcium phosphorus was calculated. The occurrence of ADR was observed. RESULTS： After 1， 2， 3 months of treatment， the levels of serum phosphate and the product of serum calcium and calcium phosphorus were all decreased significantly compared to before trreatment， with statistical significance （P＜0.05）. After 3 months of treatment， the level of corrected serum calcium was decreased significantly compared to before treatment， with statistical significance （P＜0.05）. There was no statistical significance in the levels of plasma albumin， calcium phosphorus or PTH before and after treatment （P＞0.05）. Total response rate was 93.7％. There were 19 cases of patients with mild adverse reactions. CONCLUSIONS： Lanthanum carbonate in the treatment of hyperphosphatemia in uremic patients underwent maintenance hemodialysis shows good clinical response rate， can significantly reduce the levels of serum phosphate and the product of serum calcium and calcium phosphorus with good safety.